Neurocrine Biosciences (NBIX) Return on Sales (2010 - 2026)

Neurocrine Biosciences has reported Return on Sales for 17 years, with the latest figure at 0.0% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales changed 0.0% year-over-year to 0.0%; the trailing twelve-month figure through Mar 2026 stood at 0.0% (changed 0.0% YoY), and the FY2025 full-year result was 0.0%, changed 0.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.0%, up from 0.0% in the prior quarter.
• The five-year high for Return on Sales was 0.0% in Q4 2023, with the low at 0.01% in Q2 2022.
• Historically, Return on Sales has averaged 0.0% across 5 years, with a median of 0.0% in 2023.
• Annual changes were most pronounced in 2022 — Return on Sales slipped 1 bps — and 2023, when it gained 1 bps.
• Neurocrine Biosciences' Return on Sales stood at 0.0% in 2022, then surged by 33 bps to 0.0% in 2023, then sank by 43 bps to 0.0% in 2024, then climbed by 16 bps to 0.0% in 2025, then rose by 27 bps to 0.0% in 2026.
• The last three Return on Sales figures came in at 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025), per Business Quant data.